Continuing its lookout for promising assets after its failed bid to acquire Belgian company, Ablynx, Novo Nordisk has entered into a research collaboration to develop peptide therapeutics with Kallyope for the treatment of diabetes and obesity. The collaboration provides Novo Nordisk with an option to license exclusive global rights of up to six therapies discovered with Kallyope’s platform which interrogates the gut-brain axis. Kallyope will receive an undisclosed upfront payment with license fees, milestone payments and royalties if Novo Nordisk chooses to exercise its option.